Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
about
Therapeutic Implications for Overcoming Radiation Resistance in Cancer TherapyCan Aspirin and Cancer Prevention be Ageless Companions?Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancerCurrent evidence linking polyunsaturated Fatty acids with cancer risk and progressionCellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid.Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies.Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.Inflammation and cancer: role of annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma.Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvementMolecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell LineAssociation of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis.Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells.Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2.Inhibitory effects of traditional herbal formula pyungwi-san on inflammatory response in vitro and in vivoClinical evidence for the use of aspirin in the treatment of cancer.PGE2-EP3 signaling exacerbates intracerebral hemorrhage outcomes in 24-mo-old miceThe Antitumor Effects of Triterpenoid Saponins from the Anemone flaccida and the Underlying MechanismProstaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway.Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.Deorphaning the Macromolecular Targets of the Natural Anticancer Compound Doliculide.Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis.High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study.COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway."Dead Cells Talking": The Silent Form of Cell Death Is Not so Quiet.Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cellsGPCR Signaling Mediates Tumor Metastasis via PI3KβProstaglandin dehydrogenase is a target for successful induction of cervical ripening.Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
P2860
Q26777016-C4A66CF9-587A-421E-83B8-F2B479D4CF29Q26827455-6CBA7EEE-F32C-41BF-A9A2-325371E38B46Q26828414-D202B501-5E7B-47A8-A931-EC01A9490C84Q27022573-623AE836-EC00-4D34-A175-1BE2A3B95B00Q33458922-8CCAC151-864B-4751-8647-F58023B477D3Q33592828-F1C4E117-7AAA-4046-AAFB-0A69FB050649Q34705013-D74A9324-A2E1-4903-A0D1-8AB0F676FB2EQ35504831-9CE007FB-01E2-407D-B5AC-41530493E3A8Q36177081-D370AF9D-3045-4ECC-887E-E0527655AF8AQ36215333-F6EC6DD6-330D-4371-9B4D-E4D2E3EC18E8Q36355984-8BC019BF-6EF4-40D7-82F4-25FDC50F8032Q36407288-E24F5B00-56BF-447F-86E1-4248D7E5DA85Q36420170-D3E42204-7436-4DC0-9E29-E3DE26D9A347Q36424854-5544E8D9-AE6C-4B77-B1EF-4794C7911CDAQ36557393-3492FA8F-A8AF-4573-B438-FC521165EC0FQ36561589-2388B7F3-122A-4798-B180-C200111EB415Q36643655-19821FAA-1EA2-46E7-B37E-F4A7C9406F57Q36711029-670D1573-382C-4940-BD76-DDE1D23DF2C1Q36711577-F831188B-993F-44B5-BAAA-DED7141B66B1Q36755018-7204C1BB-4721-4344-BC09-5277114619BEQ37071949-2F28D18F-9C33-4C8F-8780-9E6157FF47DBQ37244074-3E57746C-30F5-4F4D-9D5A-0F105F3952FFQ37470737-A39A604C-8C7A-4874-8C2D-FD0EE8D064FFQ37513938-B36364D6-1856-4EEB-9843-5BF8ED112518Q37701635-6824B55D-9515-406D-9492-63C2FA5BE720Q38760434-C3ED2502-AAF2-426A-9C84-20C6D0E983F6Q38823478-624A07D3-9F51-4035-A544-DDE8B45B4D5AQ38927355-095C7A16-41F5-44BC-A345-671C4CCED35FQ38997789-F37F3705-3A6E-4484-9F76-6ECC925058E4Q39198882-46731C8F-B5CF-472F-B15F-B7086534FA57Q39236102-6D9BF00F-F88C-4958-97FE-2F1B4016F28CQ40080923-5E09A15E-6DD1-49AD-AD66-3320689750BCQ40855155-EBBDA7A0-A87B-4C48-AAFE-869C3421FC84Q41981106-F5F65FA8-CD5B-4E29-B7CF-14346D3A45C9Q42199704-566E7242-35BA-4BD2-84D4-9A46EA24693EQ42586240-02A88517-4834-46BD-B17F-03745689FBE9Q48112862-B7970510-0F4C-4D0B-9A67-8DF4364C0303Q49092861-2813A328-49F7-45FA-9475-CF717D64384CQ53176610-1BAD8DDD-C99C-4A4E-9D66-71DEF550718EQ55230010-550DB10E-2E86-40A7-94D0-853930FFCA66
P2860
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@ast
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@en
type
label
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@ast
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@en
prefLabel
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@ast
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@en
P2093
P2860
P1476
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
@en
P2093
Amy Fulton
Jocelyn Reader
P2860
P2888
P304
P356
10.1007/S10555-011-9303-2
P577
2011-12-01T00:00:00Z